Last reviewed · How we verify

NCT03613246: FOLLOW

NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population

Active, enrolled Last updated 17 November 2025
What this trial tests

trial in Transcatheter Aortic Valve Implantation in 346 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 February 2019
Primary endpoint
20 December 2024
26 January 2029

Quick facts

Lead sponsorNVT GmbH
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment346
Start date20 February 2019
Primary completion20 December 2024
Estimated completion26 January 2029
Sites14 locations across Italy, Finland, Netherlands, United Kingdom, Germany, Spain

Conditions studied

Sponsor

NVT GmbH

Who can join

18 and older, any sex, with Transcatheter Aortic Valve Implantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study collects real-world data of patients who were treated with the ALLEGRA TAVI System TF and evaluates early and midterm clinical and quality of life outcome.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A European update on transcatheter aortic valve implantation (TAVI) in the COVID era.
    Antony I, Mehari Abraha H, Hameed A, Conway C. · · 2023 · cited 6× · PMID 36152032 · DOI 10.1111/joa.13740

Verify or expand the search:

Other recruiting trials for Transcatheter Aortic Valve Implantation

Currently open trials in the same condition.

Other NVT GmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03613246.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing